Not a good buy right now at 119.35 because price is pressing into near-term resistance (R1 ~120.73) with momentum starting to cool (MACD histogram still >0 but contracting).
Trend is still bullish (stacked moving averages), so this is a hold/accumulate-on-dip setup rather than a chase.
If you insist on entering immediately (impatient scenario), the risk/reward is less attractive at resistance; the cleaner entry is on a pullback toward ~117.9 (pivot) or on a decisive breakout above ~120.7.
Next meaningful catalyst is earnings (2026-02-23 after hours), which can re-rate the stock either direction; without fresh news flow, upside may be incremental in the very short term.
Technical Analysis
Trend: Bullish structure with SMA_5 > SMA_20 > SMA_200, indicating a sustained uptrend.
Momentum: MACD histogram = 0.286 (above 0) but positively contracting → still bullish, but upside momentum is slowing.
RSI: RSI_6 = 63.34 (neutral-to-bullish, not overbought) → room to run, but not an “early” oversold entry.
Levels: Pivot/support near 117.88; deeper supports 115.02 and 113.26. Resistance at 120.73, then 122.49.
Tactical read: Price is close to R1, so the most likely near-term outcome is either a breakout attempt above ~120.7 or a mean-reversion back toward ~118.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning/Sentiment: Put/Call OI ratio 0.06 is extremely call-heavy → bullish sentiment/positioning (or low hedging demand).
Activity: Very thin trading (today volume 1; puts 0), so sentiment signals are directionally bullish but low-confidence due to minimal volume.
Volatility: IV 30d ~30.38 vs HV ~25.7 (modest premium). IV percentile 7.17 / IV rank 3.64 → options pricing is relatively cheap vs its own history (market not expecting big moves).
Interpretation: Options market is calm and skewed bullish; not signaling fear into the next few sessions.
Net Income: 80,834,234.71, +11.04% YoY (profit growing faster than revenue).
EPS: 0.21, +10.53% YoY.
Gross Margin: 66.59, +4.85% YoY (margin expansion supports quality of earnings and operating leverage).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent changes:
2026-01-05 (Bradesco BBI): Upgraded to Outperform from Neutral; $120 PT (very near current price ~119.35, implying limited near-term upside from that specific target).
2025-12-19 (Barclays): Kept Overweight; raised target to MXN 297 from MXN 286 citing positive master development program negotiation outcome.
Wall Street pros view: improving strategic/regulatory outlook (master development program) and solid operating/financial momentum.
Wall Street cons view: at least one PT (Bradesco $120) is close to spot, suggesting some analysts see the stock as nearer fair value in the short run rather than deeply undervalued.
Flows/participants: Hedge funds and insiders are reported Neutral (no notable trend). Politician/congress trading: no recent data.
Wall Street analysts forecast OMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMAB is 127.5 USD with a low forecast of 120 USD and a high forecast of 135 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast OMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMAB is 127.5 USD with a low forecast of 120 USD and a high forecast of 135 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 119.580
Low
120
Averages
127.5
High
135
Current: 119.580
Low
120
Averages
127.5
High
135
Bradesco BBI
Neutral -> Outperform
upgrade
$120
AI Analysis
2026-01-05
Reason
Bradesco BBI
Price Target
$120
AI Analysis
2026-01-05
upgrade
Neutral -> Outperform
Reason
Bradesco BBI upgraded OMA to Outperform from Neutral with a $120 price target.
Barclays
NULL -> Overweight
maintain
$286 -> $297
2025-12-19
Reason
Barclays
Price Target
$286 -> $297
2025-12-19
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on OMA to MXN 297 from MXN 286 and keeps an Overweight rating on the shares. The firm cites the company's positive result from its master development program negotiation for the target boost.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OMAB
